Biopharmaceutical firm VBI Vaccines has expanded its collaboration with the Canadian government, with the latter contributing the remaining CAD$28...

Qlaris Bio, Inc., a biotechnology firm focusing on ophthalmic diseases, has announced the initiation of two Phase II clinical...

The Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive...

At the 2024 SCOPE Summit, Laura Galuchie, Senior Director and TransCelerate Program Lead at Merck provided a fresh perspective...

In the rapidly evolving landscape of digital health technology in clinical trials (DHT), Jeremy Wyatt, CEO of ActiGraph, envisions...

The MRD (Minimal Residual Disease) testing market is experiencing substantial growth, with its value projected to increase from $1.67...

Zai Lab Limited, in collaboration with Bristol Myers Squibb, announced significant progress in the fight against lung cancer with...

Pyros Pharmaceuticals, Inc., a leading company in the development of specialty pharmaceuticals for rare diseases, has announced the availability...

At the 2024 SCOPE Summit, AbbVie’s Digital Science Head, Michelle Crouthamel, presented compelling case studies on Aleve PM and...

Bristol Myers Squibb (BMY) has reported that a Phase 3 study within the YELLOWSTONE clinical trial program, which was...